Clopidogrel Bisulfate/Aspirin

Tier C — Watch / trade

Sanofi

Originator

2008

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：COXs, P2RY12

Brand：ComPlavin, DuoPlavin, Coplavix, PlavixA

Indications (approved)：Atherosclerosis, Acute coronary syndrome, Thrombosis, Myocardial infarction, Angina pectoris

Regional status

Approved

2010-03-14

China

Approved

2021-09-30

Japan

Approved

2013-09-20

Factories producing this API11

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

11 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Clopidogrel Bisulfate/Aspirin?

Approved indications include: Atherosclerosis, Acute coronary syndrome, Thrombosis, Myocardial infarction, Angina pectoris.

When does the Clopidogrel Bisulfate/Aspirin patent expire?

No public expiry year is available for Clopidogrel Bisulfate/Aspirin yet; this page updates once verified.

How do I get a quote for Clopidogrel Bisulfate/Aspirin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29